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The human pathogen Vibrio vulnificus undergoes phase variation among colo-
nial morphotypes, including a virulent opaque form which produces capsular
polysaccharide (CPS) and a translucent phenotype that produces little or no
CPS and is attenuated. Here, we found that a V. vulnificus mutant defective
for RfaH antitermination control showed a diminished capacity to undergo
phase variation and displayed significantly reduced distal gene expression
within the Group I CPS operon. Moreover, the rfaH mutant produced negli-
gible CPS and was highly sensitive to killing by normal human serum, results
which indicate that RfaH is likely essential for virulence in this bacterium.
Keywords: capsular polysaccharide; phase variation; serum survival;
transcriptional antiterminator
Vibrio vulnificus is a Gram-negative marine bacterium
that colonizes the gut of oysters and poses a significant
health risk to humans who consume raw or under-
cooked shellfish or who have wounds exposed to the
bacterium. Ingestion of the bacterium can lead to a
primary sepsis, which develops rapidly and with a sub-
stantial rate of mortality, while wound exposure can
result in a severe necrotizing fasciitis. An important
factor in disease progression is the ability of the bac-
terium to circumvent the host immune response. This
avoidance is due in large part to the presence of capsu-
lar polysaccharide (CPS), which provides resistance to
opsonization and phagocytosis, as well to the bacterio-
cidal action of complement in human serum; more-
over, CPS production by V. vulnificus masks other
immunogenic surface structures that could normally
activate nonspecific immune responses [1,2].
Vibrio vulnificus undergoes reversible phase variation
of exopolysaccharide production, including CPS, at
high frequencies and in response to various environ-
mental cues [3–5]. Phase variable colonial morphotypes
include opaque, which produces CPS and is highly vir-
ulent in an iron-loaded mouse model, and translucent,
which expresses little or no CPS and is greatly attenu-
ated for virulence [2]. A third colonial phenotype is
rugose, which expresses a separate exopolysaccharide
and is virulent if it also produces CPS [6]. Multiple
underlying genetic or epigenetic mechanisms appear to
exist for phase variation in V. vulnificus. Beginning
with an opaque parental strain, Chatzadaki-Livanis
et al. [7] found that deletions of the wzb gene within
the Group I CPS biosynthesis, transport, and assembly
operon resulted in phase-locked translucent variants;
meanwhile, no alterations within this operon were
observed for translucent derivatives that could still
reversibly switch back to opaque.
In a variety of Gram-negative bacteria, the produc-
tion of surface components, including
Abbreviations
CPS, capsular polysaccharide; LB, Luria–Bertani; LPS, lipopolysaccharide; NHS, normal human serum.
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exopolysaccharides, biofilm, and lipopolysaccharide
(LPS), as well as other secreted virulence factors, is
known to be regulated by the transcriptional antitermi-
nator RfaH. The RfaH protein allows RNA poly-
merase to proceed past Rho-dependent termination
sites without interrupting transcription, thereby
improving processivity and preventing polarity within
cognate operons [8,9]. An operon polarity suppressor
(ops) is found upstream of the first gene within RfaH-
controlled operons, and it is composed of a short
highly conserved sequence, which functions by recruit-
ing RfaH to the transcription elongation complex
[8,9]. Mutations in the rfaH gene generally result in
attenuation but the specific effects on virulence-related
functions can vary. For example, while an rfaH
mutant of uropathogenic Escherichia coli showed an
altered LPS phenotype, produced less K15 capsule and
alpha hemolysin, and was less resistant to human
serum [10], a Yersinia enterocolitica rfaH mutant pro-
duced less LPS and was attenuated in its stress
response, but was more resistant to serum killing [11].
An ops element was previously identified within the
Group I CPS operon of V. vulnificus, which implies
RfaH control of CPS production in this bacterium
[12]; however, no characterization of RfaH regulation
in V. vulnificus, or in any other Vibrio spp., has so far
been performed. Here, we assessed the effects of inser-
tion into the rfaH gene of V. vulnificus on CPS pro-
duction and gene expression, as well as serum
resistance. We found that the rfaH mutant appeared
translucent on agar media and showed a reduced
capacity to switch phases. Additionally, distal gene
expression with the Group I CPS operon and CPS
production were greatly reduced and serum resistance
appeared to be abolished. As discussed later, our find-
ings may have implications for recent efforts aimed at
producing a stable vaccine strain for this pathogen.
Materials and methods
Bacterial strains and culture conditions
Vibrio vulnificus opaque clinical isolates YJO16 [13] and
1003(O) [14] have been described previously. Vibrio
vulnificus strains were grown in heart infusion broth (Difco,
Detroit, MI, USA) supplemented to 2% NaCl (HI broth)
with 0.2% arabinose, and appropriate antibiotics. For
growth on agar plates, 0.2% arabinose and 18 g of agar
(Difco) per liter of HI were added along with necessary
antibiotics. All broth cultures were incubated at 30 °C and
shaken at 200 r.p.m.; plates were incubated overnight for
16–24 h at 30 °C. Phenotypic switching assays were per-
formed as described previously using Luria–Bertani (LB)
broth supplemented to 2% NaCl (LB2 broth) and 1 mM
CaCl22H2O [3]. Escherichia coli strain BRL2288 [15],
which was used for cloning, and strain S17.1 [16], which
was used for intergeneric conjugations, have been described
and were grown on LB plus appropriate antibiotics at
37 °C for 16–24 h.
Construction of an rfaH mutant
A 1160-bp chromosomal region containing the rfaH gene
was amplified via PCR using primers RfaH-R (50-TCTA
GAGTCAGGTCGAGCAGTGAAAG-30) and RfaH-F,2
(50-CTGCAGGTACACCAATCCTGTGTAGG-30) and
purified YJO16 genomic DNA (gDNA), which was isolated
as previously described [6]. Conditions for PCR were as
detailed previously [17]. Following digestion with XbaI and
PstI, the resulting fragment was cloned into these same sites
on plasmid pSP72 (Promega, Madison, WI, USA) to create
pVV37. The insert region of pVV37 was confirmed by
sequencing with relevant primers and BigDye v3.1 (Applied
Biosystems, Foster City, CA, USA) according to the manu-
facturer’s protocol. An 840-bp nonpolar kanamycin-resistant
cassette [18], which was obtained following digestion of plas-
mid pKan2 [17] with SmaI, was then inserted in the correct
orientation at the XmnI site of the cloned rfaH gene creating
pVV38. This meant that the cassette was inserted following
the 110th bp of the 507-bp rfaH gene. The 2-kb XbaI-PstI
fragment containing the cassette flanked by rfaH sequence
was made blunted-ended using Klenow fragment; it was then
cloned into the suicide vector pGP704sacB28 [19] at the plas-
mid’s XbaI site, which had also been blunt-ended by using
Klenow. The resulting plasmid, pVV39, was subsequently
transformed into E. coli S17.1. Kanamycin-resistant, ampi-
cillin-sensitive transconjugants, which resulted from double
homologous recombination, were obtained from matings
between E. coli S17 harboring pVV39 and V. vulnificus
YJO16, which were performed as described previously [17].
Proper integration of the cassette was verified by PCR [6]
using Amplitaq polymerase and primers RfaH-R, and RfaH-
F,2. Southern blot hybridizations using radiolabeled probes
for either the rfaH gene or the kanamycin resistance gene
from plasmid pKan2 were performed as described previously
[17] in order to confirm the rfaH mutant strain, which was
designated YJ-01.
Complementation of YJ-01
A 703-bp region containing the rfaH gene was amplified
via PCR using primers RfaH-F,3 (50-CTGC
AGTAGTCTGGCGAAATGCTAGG-30) and RfaH-R
(50-TCTAGAGTCAGGTCGAGCAGTGAAAG-30) and
purified YJO16 gDNA. The PstI- and XbaI-digested rfaH
fragment was then cloned into these same sites on plasmid
pSP72 to generate pVV59b. The insert region of the nas-
cent plasmid was sequenced by using primers RfaH-F,3
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and RfaH-R, and the method described in the previous sec-
tion. The cloned rfaH gene was then released from pVV59b
following digestion with PstI and XbaI, and was inserted
into these same sites behind the arabinose-inducible pro-
moter on the chloramphenicol-resistant plasmid
pBBRBAD2 [17] to create pVV60. Introduction of pVV60
or pBBRBAD2 into V. vulnificus YJ-01 was performed by
intergeneric mating as described earlier.
Growth curves
Growth curves were performed according to Garrison-Schil-
ling et al. [3] with minor modifications. Briefly, four indepen-
dent colonies of each strain were inoculated into 3 mL of HI
broth containing 0.2% arabinose and appropriate antibi-
otics, and these cultures were shaken overnight at 30 °C.
Overnight cultures were diluted into 5 mL HI to an
OD600 = 0.01 and incubated at 30 °C with shaking. OD600
readings were taken at 2, 4, 6, 9, and 24 h and each overnight
culture was also spread on HI agar with 0.2% arabinose and
appropriate antibiotics to confirm the absence of switching.
Reverse transcription quantitative real-time PCR
Total RNA was isolated by the method described by Grau
et al. [6] from cultures grown to an OD600 = 0.4. Primers
for reverse transcription quantitative real-time PCR (RT-
qPCR) were tested by standard PCR and subsequent agar-
ose gel electrophoresis using YJ016 gDNA. To generate
cDNA, first strand synthesis was performed on 200 ng of
clean RNA (A260/A280 = 2.0) using Superscript
 II (Invitro-
gen, Carlsbad, CA, USA) [6]. Primer efficiencies to deter-
mine appropriate primer and cDNA concentrations were
conducted in duplicate using five sequential 1 : 10 dilutions
of V. vulnificus YJ016 cDNA for the wza and wbfY genes,
as well as the tufA reference gene, with controls that
included water with reverse transcriptase (RT), gDNA with-
out RT, and a nontemplate control (NTC) in a 96-well opti-
cal plate, which was run on the ViiA7 Real-Time PCR
System (Applied Biosystems, Carlsbad, CA, USA) using
SYBR Select Master Mix chemistry (Applied Biosystems).
Numerical efficiency was determined by the formula
E = 10(1/slope)  1, and all calculations were made with the
EXPRESSIONSUITE software v1.0.3 (Applied Biosystems). RT-
qPCR was conducted on each sample versus each gene tar-
get in triplicate with 0.5 lL of appropriate 20 mM forward
and reverse primers, 5 lL of cDNA, 12.5 lL SYBR Select
Master Mix, and nuclease-free water to 25 lL. Samples
were run alongside NTC, gDNA without RT, and water
with RT controls on 96-well plates in the ViiA7 Real-Time
PCR System. Gene expression was determined using the
ΔΔCt method for relative quantification within the accom-
panying EXPRESSIONSUITE software v1.0.3 (Life Technologies,
Carlsbad, CA, USA). Each assay was repeated five times.
Human serum assay
Overnight HI cultures containing appropriate antibiotics
were diluted 1 : 100 in 3 mL fresh HI media and grown to
an OD600 = 0.45. Assays were based on the protocol previ-
ously described [20]. Cultures were spun down at 10 000 g,
washed once with phosphate-buffered saline (PBS), and
then resuspended in 3 mL fresh PBS. Aliquots of approxi-
mately 4 9 107 CFU were removed, adjusted to 350 lL
with PBS, and mixed with 650 lL of PBS, normal human
serum (NHS) from AB plasma (Sigma, St. Louis, MO,
USA), or killed NHS; the final reactions were then incu-
bated at 37 °C for 1 h. Killed NHS was obtained by incu-
bating NHS at 56 °C for 30 min and then cooling to room
temperature. Additional aliquots of the original cell suspen-
sions (again of approximately 4 9 107 CFU) were serially
diluted, and duplicate 100-lL aliquots from the 105, 106,
and 107 dilutions were plated on HI agar with relevant
antibiotics in order to determine CFUs at time zero. After
incubation, reactions were removed from the heat block
and also plated in duplicate but at every serial dilution
from 100 to 107. Plates were incubated at 30 °C for
16–24 h prior to counting and the resulting CFU scores
were then averaged for each strain. The assay was repeated
at least three times for each strain.
Isolation and analysis of CPS
Capsular polysaccharide was isolated using the protocol by
Lee et al. [21] with some modifications. Strains were grown
overnight as 3-mL HI cultures containing appropriate
antibiotics at 30 °C with shaking. Aliquots (100 lL) were
spread on HI agar with appropriate antibiotics at 30 °C for
48 h. Bacterial lawns for each strain were aseptically
removed from plates and suspended in 10 mL PBS at an
OD600 = 100. Suspensions were incubated at 30 °C with
shaking at 200 r.p.m. for 1 h and then centrifuged at
5000 g at 4 °C for 15 min. Pellets were washed with 0.45%
NaCl, resuspended in 10 mL buffer (0.45% NaCl, 1%
EDTA), and incubated at 4 °C for 1 h. Samples were then
centrifuged at 10 000 g at 4 °C for 1 h and subsequently
filtered with sterile 0.2 lm syringe filters. Filtered samples
were treated with RNaseA, DNase I, and proteinase K, all
as previously described [21]. Following extraction with phe-
nol : chloroform (50 : 50) and chloroform, CPS was pre-
cipitated with 95% ethanol, washed with 70% ethanol,
dried, and finally resuspended in distilled water. Equivalent
volumes of the purified CPS extracts were then elec-
trophoresed on 8% polyacrylamide stacking gels, and the
polysaccharide was stained with Stains-All (SigmaAldrich.
com) as described previously [22]. Two independent CPS
isolations were performed for each strain. The galacturonic
acid content in the CPS extracts was determined by using
the colorimetric assay described previously [23]. The esti-
mated carbohydrate concentration was expressed as ng of
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galacturonic acid per lL of extract. From the two CPS iso-
lations, a total of six galacturonic acid assays were per-
formed with three replicates of each strain per assay.
Statistical analysis
ANOVA statistical analysis was conducted in Excel (Micro-
soft 2007) or by using SPSS software (IBM Corporation,
Armonk, NY, USA). Statistical outputs were adjusted with
Bonferroni’s correction, a conservative method to control
the familywise error rate in multiple comparisons. P values
of ˂ 0.05 were considered significant.
Results
An rfaH mutant of V. vulnificus shows a reduced
propensity for phase variation
When a nonpolar kanamycin-resistant cassette was
inserted into the rfaH gene (see Materials and methods
for details) of opaque clinical isolate YJ016 (Fig. 1A),
the resulting mutant, designated YJ-01, displayed a
translucent phenotype on HI agar medium (Fig. 1B).
Complementation using a cloned version of rfaH on
the arabinose-inducible expression vector pBBRBAD2
(i.e., plasmid pVV60) restored opacity to YJ-01
(Fig. 1D), while, as expected, addition of the vector
alone did not (Fig. 1C).
The capacity of the rfaH mutant to undergo pheno-
typic switching was assessed by subjecting it to our
previously describing switching assay, which includes
daily passaging of strains in broth media with plating
for individual colonies at regular intervals and subse-
quent counting and scoring of colonial phenotypes [3].
After 15 daily passages, 99.8% of the colonies of the
translucent derivative YJ-01 remained translucent and
no switching to either opaque or rugose had occurred
(Fig. 2); the very few nontranslucent colonies seen for
YJ-01 at 15 passages were of an indeterminant pheno-
type. This apparent lack of switching for YJ-01 was
reminiscent of the phase-locked phenotype seen previ-
ously for translucent phase variants that had acquired
deletions of the wzb gene, and it was in contrast to
prior results for translucent variants that did not con-
tain such CPS gene deletions and thus still underwent
phase variation at readily detectable frequencies [7].
Meanwhile, switching here of the parental strain
YJ016 was detected initially after 10 passages and, by
15 passages, 8.3  8.3% of resulting colonies of YJ016
had switched from opaque to translucent, which was
consistent with previous results for this strain [3]. The
results for YJ016 were also similar to the comple-
mented mutant YJ-01(pVV60) of which 17.3  9.9%
of its colonies had switched from opaque to translu-
cent by 15 passages and 0.9  0.7% had switched to
rugose (Fig. 2). Growth curves for strain YJ-01 were
nearly identical to those of the parent (Fig. S1), which
indicated that the reduced capacity of the rfaH mutant
to undergo phase variation was unlikely due to a puta-
tive indirect effect associated with slower growth.
RfaH controls CPS production in V. vulnificus at
the transcriptional level
Typically, mutations in the rfaH gene lead to substan-
tial decreases in distal gene transcription of RfaH-con-
trolled operons, while proximal gene expression
remains largely unaffected [8]. We examined the
potential effects of rfaH inactivation on distal (wbfY)
and proximal (wza) transcription of the Group I
CPS operon [7] by isolating total RNA from mid-
exponential cultures of YJ016, YJ-01, YJ-01
(pBBRBAD2), and YJ-01(pVV60), and quantifying
transcription of these genes using RT-qPCR. As
shown in Fig. 3, while there was little difference in
expression of wza in the rfaH mutant YJ-01 compared
to the parent YJ016, relative expression of wbfY was
reduced over 25-fold (i.e., down to 0.03  0.39) and
this difference was considered significant based on an
ANOVA analysis with adjustment by a Bonferroni
post hoc test (P ˂ 0.001). As expected, the addition of
A B
C D
Fig. 1. Phenotype of the rfaH mutant YJ-01. Vibrio vulnificus
strains were streaked on HI agar containing 0.2% arabinose (and
kanamycin and chloramphenicol where appropriate) and incubated
overnight at 30 °C. Panels: A, YJO16; B, YJ-01; C, YJ-01
(pBBRBAD2); D, YJ-01(pVV60).
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plasmid pVV60, but not pBBRBAD2, to YJ-01
restored transcription of wbfY to a level that was not
significantly different (P = 0.354) from that of YJ016
(Fig. 3).
To assess the potential effect on CPS production of
reduced distal gene expression of the Group I operon,
CPS was extracted from approximately equivalent
numbers of cells of these same strains and the amount
of galacturonic acid, which has previously been shown
to be a component of V. vulnificus CPS [21], was
quantified by using a colorimetric assay. As shown in
Fig. 4A, the quantity of galacturonic acid was negligi-
ble for YJ-01 (2.3  2.1 nglL1 of extract) relative to
YJ016 (66.7  14.4 nglL1) and this difference was
considered to be significant (P ˂ 0.002). Complementa-
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Fig. 2. Evidence of a reduced propensity for phase variation for the rfaH mutant. Phenotypic switching assays were performed as described
[3] for a total of 15 passages for strains YJO16 (black bars), YJ-01 (white bars), and YJ-01(pVV60) (gray bars) in LB2 broth supplemented
with 1 mM CaCl2·2H2O. Dilutions and platings of the initial overnight culture and following 5, 10, and 15 passages were conducted in order
to count and score colony phenotypes. Phenotypes were scored as opaque, translucent, rugose, sectored, which were two phenotypes in
one colony, and indeterminant, which included any other uncharacterized phenotype. At each sampling time, the proportions of opaque (O),
translucent (T), and rugose (R) colonies to the total number of colonies were calculated and multiplied by 100 for three independent




















YJ-01 YJ-01 + pBBRBAD2YJO16 YJ-01 + pVV60
Fig. 3. Reduced distal gene transcription within the Group I CPS operon in the rfaH mutant. Total RNA was extracted from mid-exponential
cultures of the indicated strains and subjected to RT-qPCR analysis. The graph depicts the expression differences of the wza (black bars)
and wbfY (white bars) genes in YJ-01, YJ-01(pBBRBAD2), and YJ-01(pVV60) relative to their expression in YJ016. All data were normalized
with respect to the tufA reference gene. Reactions were performed in triplicate and the entire assay was repeated five times with the
average relative expressions  SE being presented here.
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47.5  9.0 nglL1, which was not significantly differ-
ent from the amount seen for YJ016 (P = 0.123). The
concentrations of galacturonic acid determined from
these assays also correlated with the relative amounts
of total CPS present in these same extracts as
determined by polyacrylamide gel electrophoresis and
subsequent staining with Stains-All (Fig. 4B).
Loss of RfaH results in extreme serum sensitivity
of V. vulnificus
Given the role of CPS in serum resistance in V. vulnifi-
cus, we next subjected these strains to standard serum
resistance assays in which approximately
4 9 107 CFU per strain were exposed to NHS for 1 h
at 37 °C, and the survivors were then quantified fol-
lowing plating. We found that the rfaH mutant YJ-01




























YJO16 YJ-01 YJ-01 YJ-01
+ pBBRBAD2 + pVV60
A
B
Fig. 4. Decreased CPS production by the rfaH mutant. Based on the
method described by Lee et al. [21], CPS was extracted from
approximately equivalent numbers of plate-grown cells of the
indicated strains. (A) Galacturonic acid content of CPS extracts.
Galacturonic acid content of isolated CPS was determined by using a
colorimetric assay [21], and from a total of six assays, the average
concentrations of galacturonic acid in nglL1 of CPS extract  SD
are presented. (B) Qualitative assessment of CPS concentration in
extracts. Equivalent volumes of CPS extracts were electrophoresed
on 8% polyacrylamide stacking gels and stained with Stains-All. Two
independent isolations of CPS from each strain were performed with





















Fig. 5. Sensitivity of the rfaH mutant to normal human serum.
Equivalent aliquots of each of the indicated strains were either
serially diluted and plated to determine CFUs at time zero or they
were mixed with normal human serum, and after 60 min of
incubation, the reactions were serially diluted, plated, and the
surviving CFUs were determined. The assay was repeated at least
three times for each strain and the geometric means  SD are
presented. Symbols: (●), YJ016; (○), YJ-01; (▲), YJ-01
(pBBRBAD2); (Δ), YJ-01(pVV60); (♦), 1003(O); (◊), ABZ1(T).
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resistance by approximately 5 orders of magnitude rel-
ative to the parent YJ016 (Fig. 5). As expected, addi-
tion of pVV60, but not pBBRBAD2, restored high-
level resistance of YJ-01. The results here contrasted
sharply with those obtained in control assays in which
NHS was replaced by heat-inactivated human serum
or PBS; in those cases, the mutant YJ-01 survived as
well as YJ016 (data not shown), which is consistent
with the view that YJ-01 was sensitive to the active
complement system present in NHS.
To provide further context regarding the sensitivity
of strain YJ-01 to NHS, we compared its results to
another translucent strain ABZ1(T), which is a deriva-
tive of opaque clinical isolate 1003(O). Strain ABZ1(T)
contains a previously described transposon insertion in
an epimerase gene that was shown to be essential for
CPS production [24]; moreover, ABZ1(T) was found
to be greatly attenuated, such that in multiple studies,
it did not kill any iron-loaded mice at doses as high as
4.9 9 107 CFU [6,24]. Here we found that while the
parental strain 1003(O) showed resistance to NHS at a
level similar to YJ016, ABZ1(T) was reduced signifi-
cantly in resistance (P ˂ 0.001) by approximately 4
orders of magnitude (Fig. 5). Although ABZ1(T) typi-
cally yielded somewhat more survivors than YJ-01 fol-
lowing exposure to NHS, we found no significant
difference overall between them in these assays
(P = 1.000); thus, we conclude that the rfaH mutant
YJ-01 of V. vulnificus is as sensitive to serum killing as
the potentially avirulent and acapsular translucent
strain ABZ1(T).
Discussion
Although RfaH antitermination appears to be a well-
conserved mechanism among Gram-negatives, the
specific secreted factors and surface molecules con-
trolled by RfaH vary from species to species. Here, we
assessed the effects of rfaH gene inactivation in V. vul-
nificus on expression of the Group I CPS operon and
found conclusive evidence that RfaH plays a signifi-
cant role in CPS production and serum resistance in
this bacterium. A considerable number of virulence
factors have been identified in V. vulnificus, including
siderophores, LPS, CPS, pili, flagella, certain outer
membrane proteins and several toxins; however, due
to its central role in protecting the bacterium from the
host immune response, CPS is one of the few factors
recognized as being absolutely essential for pathogenic-
ity [2,25,26]. Our results here suggest that the
RfaH protein itself is also essential for the ability of
V. vulnificus to cause disease because of its critical role
in transcription of CPS genes.
There is at least one additional target of RfaH in
V. vulnificus as an ops element was also identified
within the brp operon [6]. This set of genes encodes
functions required for rugosity and production of the
exopolysaccharide associated with rugose cells, and
transcription of the brp genes was found to be highly
up-regulated in rugose compared to opaque and
translucent variants [6,27]. Eventual characterization
of RfaH control of rugosity in V. vulnificus would
require construction of an rfaH mutant beginning with
a rugose parent rather than the opaque one used here
and assessment of the effects of this defect on brp
operon transcription and rugose exopolysaccharide
production. The potential for reduced distal gene tran-
scription within both the Group I CPS and brp oper-
ons in rfaH mutant cells may explain why we did not
observe switching here of strain YJ-01 to either opa-
que or rugose.
An additional polysaccharide controlled by RfaH in
some bacteria is the O-antigen of LPS, and, like CPS,
O-antigen is considered to be a major contributor to
serum resistance [28]. While a role for O-antigen in
serum survival of V. vulnificus does seem likely [29],
the potential for rfaH control of O-antigen production
in V. vulnificus is at present unclear as little is known
about the genetic determinants of LPS synthesis in this
organism [29–31].
There have been a number of efforts over the years
aimed at developing effective vaccines for V. vulnificus,
including recent attempts involving either subunit or
whole-cell candidates [32–35]. A recently described
attenuated mutant defective for production of three
different cytotoxins resulted in an induced antibody
response to V. vulnificus and provided protection in
mice against challenge with a virulent strain [32]. In
the last decade, the use of rfaH mutants as a basis for
live attenuated Salmonella enterica vaccine strains has
shown promise [36–40]. Our results here demonstrating
that strain YJ-01 was defective for CPS production
raise the possibility that a V. vulnificus rfaH mutant
may also prove to be an effective attenuated vaccine
candidate. This assertion is bolstered by evidence that
loss of CPS by V. vulnificus not only results in attenu-
ation of virulence but also likely unmasks other
immunogenic surface components of this pathogen
[1,2].
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